<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-13162R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0009350</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology/Cell Signaling</subject><subject>Immunology/Immune Response</subject><subject>Cardiovascular Disorders/Myocardial Infarction</subject></subj-group></article-categories><title-group><article-title>PI3K&#x003b3; Protects from Myocardial Ischemia and Reperfusion Injury through a Kinase-Independent Pathway</article-title><alt-title alt-title-type="running-head">PI3K&#x003b3; in Ischemia/Reperfusion</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Haubner</surname><given-names>Bernhard J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Neely</surname><given-names>G. Gregory</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Voelkl</surname><given-names>Jakob G. J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Damilano</surname><given-names>Federico</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kuba</surname><given-names>Keiji</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Imai</surname><given-names>Yumiko</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Komnenovic</surname><given-names>Vukoslav</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mayr</surname><given-names>Agnes</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pachinger</surname><given-names>Otmar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hirsch</surname><given-names>Emilio</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Penninger</surname><given-names>Josef M.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Metzler</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Internal Medicine III (Cardiology), Innsbruck Medical University, Innsbruck, Austria</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Genetics, Biology and Biochemistry, Molecular Biotechnology Center, University of Torino, Torino, Italy</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kowaltowski</surname><given-names>Alicia J.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Instituto de Qu&#x000ed;mica, Universidade de S&#x000e3;o Paulo, Brazil</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>josef.penninger@oeaw.ac.at</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: BJH GGN KK YI OP EH JMP BM. Performed the experiments: BJH GGN JGJV FD KK YI VK AM. Analyzed the data: BJH GGN JGJV AM JMP BM. Contributed reagents/materials/analysis tools: OP EH JMP BM. Wrote the paper: BJH GGN JMP BM.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>22</day><month>2</month><year>2010</year></pub-date><volume>5</volume><issue>2</issue><elocation-id>e9350</elocation-id><history><date date-type="received"><day>25</day><month>9</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>2</month><year>2010</year></date></history><permissions><copyright-statement>Haubner et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>PI3K&#x003b3; functions in the immune compartment to promote inflammation in response to G-protein-coupled receptor (GPCR) agonists and PI3K&#x003b3; also acts within the heart itself both as a negative regulator of cardiac contractility and as a pro-survival factor. Thus, PI3K&#x003b3; has the potential to both promote and limit M I/R injury.</p></sec><sec><title>Methodology/Principal Findings</title><p>Complete PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mutant mice, catalytically inactive PI3K&#x003b3;<sup>KD/KD</sup> (KD) knock-in mice, and control wild type (WT) mice were subjected to <italic>in vivo</italic> myocardial ischemia and reperfusion (M I/R) injury. Additionally, bone-marrow chimeric mice were constructed to elucidate the contribution of the inflammatory response to cardiac damage. PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice exhibited a significantly increased infarction size following reperfusion. Mechanistically, PI3K&#x003b3; is required for activation of the Reperfusion Injury Salvage Kinase (RISK) pathway (AKT/ERK1/2) and regulates phospholamban phosphorylation in the acute injury response. Using bone marrow chimeras, the cardioprotective role of PI3K&#x003b3; was mapped to non-haematopoietic cells. Importantly, this massive increase in M I/R injury in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice was rescued in PI3K&#x003b3; kinase-dead (PI3K&#x003b3;<sup>KD/KD</sup>) knock-in mice. However, PI3K&#x003b3;<sup>KD/KD</sup> mice exhibited a cardiac injury similar to wild type animals, suggesting that specific blockade of PI3K&#x003b3; catalytic activity has no beneficial effects.</p></sec><sec><title>Conclusions/Significance</title><p>Our data show that PI3K&#x003b3; is cardioprotective during M I/R injury independent of its catalytic kinase activity and that loss of PI3K&#x003b3; function in the hematopoietic compartment does not affect disease outcome. Thus, clinical development of specific PI3K&#x003b3; blockers should proceed with caution.</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Cardiac damage in acute myocardial infarction results from a disruption of blood flow to the heart (ischemia) that may be followed by either spontaneous or therapeutically induced restoration of blood supply (reperfusion). Myocardial ischemia/reperfusion (M I/R) results in infarction due to intrinsic cardiomyocyte death <xref ref-type="bibr" rid="pone.0009350-Baines1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Hausenloy1">&#x0005b;2&#x0005d;</xref> and damage via excessive immune activation <xref ref-type="bibr" rid="pone.0009350-Nian1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Yaoita1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Fisher1">&#x0005b;5&#x0005d;</xref>. Many inflammatory factors that build up during injury exert their effects through G-protein coupled receptors (GPCRs) <xref ref-type="bibr" rid="pone.0009350-Brodde1">&#x0005b;6&#x0005d;</xref> suggesting that mediators of GPCRs might be critically involved in the M I/R damage response. One key signaling pathway downstream of GPCRs is mediated via phosphoinositide 3-kinase &#x003b3; (PI3K&#x003b3;).</p><p>Phosphatidylinositol-3-OH kinases (PI3K) are lipid kinases that convert phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate (PIP3). In mammals, there are four class I PI3K, three of which (&#x003b1;, &#x003b2;, and &#x003b4;) are primarily activated by tyrosine kinase signaling pathways, whereas PI3K&#x003b3; is the principal PI3K that relays signals via GPCRs to downstream pathways such as AKT and ERK/1/2 <xref ref-type="bibr" rid="pone.0009350-Hawkins1">&#x0005b;7&#x0005d;</xref>. PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice (lacking the catalytic subunit p110) are viable and in certain experimental settings exhibit reduced inflammation <xref ref-type="bibr" rid="pone.0009350-Hirsch1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Sasaki1">&#x0005b;9&#x0005d;</xref> as the PI3K&#x003b3; pathway controls migration of inflammatory cells <xref ref-type="bibr" rid="pone.0009350-Hawkins2">&#x0005b;10&#x0005d;</xref>. In addition, we have previously shown that PI3K&#x003b3; acts as an intrinsic negative regulator of cardiac contractility <xref ref-type="bibr" rid="pone.0009350-Crackower1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Patrucco1">&#x0005b;12&#x0005d;</xref>. Given its dual roles in cardiomyocyte function and inflammation, it is not clear if the net effect of PI3K&#x003b3; loss is cardio-protective or cardio-destructive during M I/R. For example, we have previously shown that PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice are resistant to the detrimental effects of chronic &#x003b2;-adrenergic receptor signaling <xref ref-type="bibr" rid="pone.0009350-Oudit1">&#x0005b;13&#x0005d;</xref>. Conversely, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice showed a worse outcome both in a model of chronic myocardial ischemia without reperfusion <xref ref-type="bibr" rid="pone.0009350-Curcio1">&#x0005b;14&#x0005d;</xref> and chronic pressure overload <xref ref-type="bibr" rid="pone.0009350-Patrucco1">&#x0005b;12&#x0005d;</xref>, while overexpression of catalytically inactive PI3K&#x003b3; protected from heart failure in this model <xref ref-type="bibr" rid="pone.0009350-Nienaber1">&#x0005b;15&#x0005d;</xref>. Moreover, it has been reported that a PI3K&#x003b3; blocker might protect from M I/R injury due to inhibition of the inflammatory response during reperfusion <xref ref-type="bibr" rid="pone.0009350-Doukas1">&#x0005b;16&#x0005d;</xref>. However, since such blockers are not specific for PI3K&#x003b3; and PI3K&#x003b3; inhibitors are currently developed as a novel treatment option for M I/R in humans, it is paramount to genetically define the role of PI3K&#x003b3; in cardiac ischemia/reperfusion injury.</p><p>We therefore assessed the role of PI3K&#x003b3; in M I/R injury using PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice. We report that PI3K&#x003b3; mutant mice develop massive early and late stage cardiac M I/R injury. PI3K&#x003b3; seems to be the key kinase that activates the Reperfusion Injury Salvage Kinase (RISK) pathway (AKT/ERK1/2) in the acute setting of M I/R. Using bone marrow chimeras these effects were mechanistically mapped to non-haematopoetic cells suggesting that the effects are intrinsic to cardiac tissue. To assess whether these effects are dependent on catalytic activity, we performed M I/R injury in mice with a knock-in mutation in the PI3K&#x003b3; kinase domain (PI3K&#x003b3;<sup>KD/KD</sup>). PI3K&#x003b3;<sup>KD/KD</sup> mice developed cardiac injury similar to wild type mice. Thus, PI3K&#x003b3; protects the heart from M I/R injury through a kinase-independent mechanism <italic>in vivo</italic>.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Genetic Inactivation of PI3K&#x003b3; Results in Severe Cardiac Damage to M I/R Injury</title><p>To assess the role of PI3K&#x003b3; in M I/R injury, we performed <italic>in vivo</italic> reversible LAD ligation in sex and age matched PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) mice and PI3K&#x003b3; expressing wild type mice (WT). The extent of injury and heart functions were assayed 3 hours, 24 hours, 1 week, and 3 weeks after initiation of reperfusion. Intriguingly, in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice serum Troponin T levels, a marker of cardiac damage, were significantly increased after 3 hours of reperfusion (<xref ref-type="fig" rid="pone-0009350-g001">Figure 1A</xref>), without a significant change in the number of inflammatory cells infiltrating the damaged cardiac tissue (<xref ref-type="fig" rid="pone-0009350-g001">Figure 1B</xref>). In parallel, we observed a massive increase of the infarction size within the area at risk in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> hearts at the early stage of M I/R injury (assayed at 24 hours, <xref ref-type="fig" rid="pone-0009350-g001">Figure 1C&#x02013;E</xref>). Thus, immediately after M I/R the loss of PI3K&#x003b3; expression results in massive early heart damage.</p><fig id="pone-0009350-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009350.g001</object-id><label>Figure 1</label><caption><title>Loss of PI3K&#x003b3; results in massive myocardial ischemia/reperfusion induced heart damage.</title><p>(<bold>A</bold>) Following M I/R injury, serum TroponinT is significantly increased in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) mice compared to wild type (WT) controls. Data are from 3 hours after reperfusion. n&#x0200a;&#x0003d;&#x0200a;13 per group. (<bold>B</bold>) No significant difference in the numbers of inflammatory cells in the injured hearts of PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice. Inflammatory cell infiltrates were assessed 3 hours after reperfusion. n&#x0200a;&#x0003d;&#x0200a;7 per group. (<bold>C</bold>) No significant difference in the area at risk (AAR)/left ventricle (LV) in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice. (<bold>D</bold>) PI3K&#x003b3; KO mice display a markedly increased area of infarction/area at risk (AAR) 24 hours after reperfusion. n&#x0200a;&#x0003d;&#x0200a;6 per group for (<bold>C</bold>) and (<bold>D</bold>). (<bold>E</bold>) Representative left ventricular TTC-stained sections from the basis (left) to the apex (right) of wild type (WT; upper panels) and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO; lower panels) hearts after 24 hours of reperfusion. Pale areas represent necrotic regions (arrows). Bars indicate 1 mm. In all bar graphs mean values &#x0002b;/&#x02212; SEM are shown. &#x0002a;p&#x0003c;0.05. &#x0002a;&#x0002a;p&#x0003c;0.01. NS&#x0200a;&#x0003d;&#x0200a;not significant.</p></caption><graphic xlink:href="pone.0009350.g001"/></fig><p>It was possible that in the long term the early cardioprotective effects of PI3K&#x003b3; would not outweigh secondary pro-inflammatory effects due to impaired migration of inflammatory cells into the damaged heart; therefore, the net result of disrupting PI3K&#x003b3; expression could be cardioprotective. To address this possibility we performed M I/R injury on wild type (WT) and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) mice and followed these mice for up to three weeks. One week after M I/R injury, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice still exhibited a massive increase in infarction size as compared to the control cohort (<xref ref-type="fig" rid="pone-0009350-g002">Figure 2A,B</xref>). Again we observed no significant differences in the numbers of inflammatory cells infiltrating the cardiac tissue between control and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice (<xref ref-type="fig" rid="pone-0009350-g002">Figure 2C</xref>), suggesting that PI3K&#x003b3; is not required for recruitment of inflammatory cells to the infarction site during the early (3 hours) as well as later stages (1 week) stages of M I/R injury.</p><fig id="pone-0009350-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009350.g002</object-id><label>Figure 2</label><caption><title>Loss of PI3K&#x003b3; results in long term myocardial ischemia/reperfusion induced heart damage.</title><p>(<bold>A</bold>) Areas of infarction (arrows) in representative left mid-ventricular sections 1 week after M I/R injury. (H&#x00026;E staining). Bars indicate 1 mm. (<bold>B</bold>) PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) hearts show a markedly greater infarction size in the left ventricle (LV) at 1 week after M I/R. n&#x0200a;&#x0003d;&#x0200a;7 per group. (<bold>C</bold>) No significant difference between PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> and WT mice in the numbers of infiltrating inflammatory cells 1 week after M I/R. n&#x0200a;&#x0003d;&#x0200a;7 per group. (<bold>D</bold>) Representative left mid-ventricular sections stained with Trichrome and Aniline blue to visualize collagen deposits (arrows) in hearts of PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) and wild type (WT) mice 3 weeks after M I/R. Magnifications &#x000d7;20. (<bold>E</bold>) Markedly increased scar tissue in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> 3 weeks after M I/R injury. n&#x0200a;&#x0003d;&#x0200a;7 per group. (<bold>F</bold>) PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice exhibit a significant greater loss in percentage fractional shortening (FS) relative to their respective baseline FS after 3 weeks of M I/R compared to WT controls. n&#x0200a;&#x0003d;&#x0200a;9 per group. In all bar graphs mean values &#x0002b;/&#x02212; SEM are shown. &#x0002a;p&#x0003c;0.05. NS&#x0200a;&#x0003d;&#x0200a;not significant.</p></caption><graphic xlink:href="pone.0009350.g002"/></fig><p>Following the inflammatory phase of M I/R injury, scar formation occurs at the infarction site. In both wild type and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice the primary damage site was replaced by scar tissue 3 weeks after the initial M I/R injury (<xref ref-type="fig" rid="pone-0009350-g002">Figure 2D</xref>). In line with the increased injury, collagen deposition and scar formation was markedly increased in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice (<xref ref-type="fig" rid="pone-0009350-g002">Figure 2D, E</xref>). We next assessed cardiac function 3 weeks after M I/R injury. Functionally, the excessive early damage and increased scar formation in M I/R injured PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice culminated in a severe reduction in cardiac contractility as defined by changed fractional shortening from the baseline (<xref ref-type="fig" rid="pone-0009350-g002">Figure 2F</xref>). Thus, PI3K&#x003b3; is cardio-protective during M I/R injury and genetic disruption of PI3K&#x003b3; results in severe cardiac damage that is sustained over time and severely compromises cardiac function.</p></sec><sec id="s2b"><title>PI3K&#x003b3; Affects Cardiac M I/R Injury Independent of the Haematopoietic System</title><p>PI3K&#x003b3; controls multiple activation pathways in haematopoetic cells including cell migration <xref ref-type="bibr" rid="pone.0009350-Hawkins1">&#x0005b;7&#x0005d;</xref> and it has been proposed that PI3K&#x003b3; might be a key drug target to block inflammation in various pathologic conditions including M I/R injury in heart attacks <xref ref-type="bibr" rid="pone.0009350-Ruckle1">&#x0005b;17&#x0005d;</xref>. To directly test whether the protective effects of PI3K&#x003b3; are due to its function in the immune system, we generated bone marrow chimeras. Interestingly, although PI3K&#x003b3; has clearly been implicated in inflammation in many other systems <xref ref-type="bibr" rid="pone.0009350-Hawkins1">&#x0005b;7&#x0005d;</xref>, wild type mice given either wild type or PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> bone marrow developed comparable M I/R injuries (<xref ref-type="fig" rid="pone-0009350-g003">Figure 3A, C</xref>) and showed equal Troponin T release (<xref ref-type="fig" rid="pone-0009350-g003">Figure 3D</xref>). Moreover, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> and wild type immune cells accumulated to a similar extent at the site of M I/R injury (<xref ref-type="fig" rid="pone-0009350-g003">Figure 3E</xref>).</p><fig id="pone-0009350-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009350.g003</object-id><label>Figure 3</label><caption><title>PI3K&#x003b3; functions in non-haematopoietic cells in myocardial ischemia/reperfusion injury.</title><p>(<bold>A</bold>) Representative left mid-ventricular histological sections (H&#x00026;E staining) from WT mice receiving WT bone marrow (WT&#x02192;WT) and WT mice receiving PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> bone marrow (KO&#x02192;WT). Hearts were isolated and analysed from mice 1 week after M I/R injury. Arrows indicate areas of infarction. (<bold>B</bold>) Representative left mid-ventricular histological sections (H&#x00026;E staining) from PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice receiving WT bone marrow (WT&#x02192;KO) and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice receiving PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> bone marrow (KO&#x02192;KO) after 1 week of M I/R injury. Arrows point at areas of infarction. (<bold>C</bold>) No significant difference between WT&#x02192;WT and KO&#x02192;WT chimeras and no difference between WT&#x02192;KO and KO&#x02192;KO chimeras in the size of infarction determined 1 week after M I/R injury. n&#x0200a;&#x0003d;&#x0200a;5 per group. (<bold>D</bold>) No significant difference between WT&#x02192;WT and KO&#x02192;WT chimeras and no difference between WT&#x02192;KO and KO&#x02192;KO chimeras in TroponinT levels assayed 3 hours after reperfusion. n&#x0200a;&#x0003d;&#x0200a;7 per group. (<bold>E</bold>) No significant difference between all 4 groups of chimeric mice in the numbers of infiltrating inflammatory cells 1 week after M I/R. n&#x0200a;&#x0003d;&#x0200a;5 per group. In all histological pictures the bar indicates 1 mm. All bar graphs show mean values &#x0002b;/&#x02212; SEM. &#x0002a;p&#x0003c;0.05. NS&#x0200a;&#x0003d;&#x0200a;no significant difference.</p></caption><graphic xlink:href="pone.0009350.g003"/></fig><p>In the reciprocal experiment, wild type or PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> bone marrow was transferred into PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> recipients; in these bone marrow chimeras we again observed comparable infarction sizes (<xref ref-type="fig" rid="pone-0009350-g003">Figure 3B, C</xref>) and Troponin T release (<xref ref-type="fig" rid="pone-0009350-g003">Figure 3D</xref>). Irrespective of the genotype of the transferred bone marrow cells, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> recipient mice exhibited similar inflammation at the site of infarction (<xref ref-type="fig" rid="pone-0009350-g003">Figure 3E</xref>). Of note, in all bone marrow transplantation experiments, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> recipient mice developed markedly more severe cardiac damage following M I/R injury as compared to wild type host mice (<xref ref-type="fig" rid="pone-0009350-g003">Figure 3B&#x02013;D</xref>). These data indicate that the excessive damage seen in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice following M I/R injury occurs independent of its role in haematopoietic cells.</p></sec><sec id="s2c"><title>Loss of PI3K&#x003b3; Results in Impaired RISK Signaling</title><p>Activation of the PI3K pathway leads to cell survival through activation of the Reperfusion Injury Salvage Kinase (RISK) pathway (AKT/ERK1/2) <xref ref-type="bibr" rid="pone.0009350-Hausenloy1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Hawkins2">&#x0005b;10&#x0005d;</xref>. Similar to the growth factor coupled class IA PI3Ks &#x003b1;,&#x003b2;, and &#x003b4;, PI3K&#x003b3; can relay GPCR signals to activate AKT and ERK1/2 in cardiomyocytes <xref ref-type="bibr" rid="pone.0009350-Crackower1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Patrucco1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Oudit1">&#x0005b;13&#x0005d;</xref>. To assess AKT and ERK activation in M I/R injury, we isolated hearts from wild type and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice prior to ischemia, after 30 minutes of ischemia, and 40 minutes as well as 24 hours after initiation of reperfusion. Protein extracts were isolated from the area at risk and immunoblotted for phosphorylated AKT (T308 and S473, <xref ref-type="fig" rid="pone-0009350-g004">Figure 4A</xref>) and phosphorylated ERK1/2 (T202/Y204, <xref ref-type="fig" rid="pone-0009350-g004">Figure 4B</xref>), both indicative of activate AKT and ERK1/2.</p><fig id="pone-0009350-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009350.g004</object-id><label>Figure 4</label><caption><title>PI3K&#x003b3; is the critical mediatior of AKT and ERK1/2 activation in the acute phase of ischemia/reperfusion injury.</title><p>(<bold>A</bold>) Western blot analysis of phosphorylated AKT (T308 and S473) and (<bold>B</bold>) phosphorylated ERK1/2 (T202/Y204) in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> and wild type PI3K&#x003b3;<sup>&#x0002b;/&#x0002b;</sup> hearts after sham surgery, 30 minutes of ischemia (30'I), 30 minutes of ischemia plus 40 minutes of reperfusion (30'I/40'R), and 30 minutes of ischemia plus 24 hrs of reperfusion (30'I/24hR). Total AKT and ERK1/2 levels are shown as controls. Representative data from 2 mice for each genotype and treatment protocol are shown. (<bold>C</bold>) Immunohistochemical staining for phosphorylated AKT (S473) in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) and wild type (WT) hearts after sham surgery (left panels), 30 minutes of ischemia (30'I), and 30 minutes of ischemia plus 40 minutes of reperfusion (30'I/40'R). A secondary antibody staining control is shown (control). Bar indicates 1 mm. Inserts are 20&#x000d7; magnifications. (<bold>D</bold>) Western blot analysis of wild type hearts to determine PI3K&#x003b3; expression levels in sham-treated mice, 30 minutes of ischemia (30'I), and 30 minutes of ischemia plus 40 minutes of reperfusion (30'I/40'R). Representative data from 2 mice for each genotype and treatment protocol are shown. Heart lysates from PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice are shown as a specificity control. (<bold>E</bold>) Increased phosphorylated phospholamban B (pPLB)/phospholamban B (PLB) ratios in hearts from PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice compared to wild type mice after sham surgery, 30 minutes of ischemia (30'I), 30 minutes of ischemia plus 40 minutes of reperfusion (30'I/40'R), and 30 minutes of ischemia plus 24 hrs of reperfusion (30'I/24hR). Western blot results are shown as duplicates. For all Western blots, the area at risk was dissected from the left ventricle.</p></caption><graphic xlink:href="pone.0009350.g004"/></fig><p>As previously reported <xref ref-type="bibr" rid="pone.0009350-Crackower1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Oudit1">&#x0005b;13&#x0005d;</xref>, wild type and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice exhibit comparable baseline phosphorylation of both AKT and ERK1/2. Following 30 minutes of ischemia due to <italic>in vivo</italic> LAD ligation, AKT and ERK1/2 activation were comparably reduced in both genotypes. Ischemia-induced decrease in AKT and ERK1/2 phosphorylation was rapidly restored in wild type animals within 40 minutes of reperfusion. By contrast, in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice AKT and ERK1/2 phosphorylation were still markedly reduced 40 minutes after reperfusion (<xref ref-type="fig" rid="pone-0009350-g004">Figure 4A, B</xref>). These marked differences in AKT and ERK1/2 activation were not apparent after 24 hours of reperfusion, indicating a role of PI3K&#x003b3; in the early initiation of pro-survival signaling through AKT and ERK1/2. Immunohistochemical staining to detect phosphorylated AKT (S473) showed that active AKT is localized to the area at risk of wild type hearts (<xref ref-type="fig" rid="pone-0009350-g004">Figure 4C</xref>). Of note, <italic>in vivo</italic> M I/R did not alter the PI3K&#x003b3; protein content in the early phase of reperfusion (<xref ref-type="fig" rid="pone-0009350-g004">Figure 4D</xref>). Thus, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice fail to activate AKT and ERK1/2 immediately following M I/R injury, and this lack of activation can be localized to the area at risk.</p><p>In addition to AKT and ERK1/2 activation, PI3K&#x003b3; is a regulator of myocardial contractility <xref ref-type="bibr" rid="pone.0009350-Crackower1">&#x0005b;11&#x0005d;</xref> via regulation of phosphodiesterases and subsequent phospholamban (PLB) phosphorylation in the sarcoplasmatic reticulum <xref ref-type="bibr" rid="pone.0009350-Patrucco1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Kerfant1">&#x0005b;18&#x0005d;</xref>. Phosphorylation of PLB results in increased contractility <xref ref-type="bibr" rid="pone.0009350-Crackower1">&#x0005b;11&#x0005d;</xref>. Confirming previous results, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> hearts exhibit a much higher basal level of phosphorylated PLB (<xref ref-type="fig" rid="pone-0009350-g004">Figure 4E</xref>). Whereas in wild type hearts phosphorylated PLB was decreased following ischemia and 40 minutes of reperfusion, such decrease in phosphorylated PLB was less pronounced in ischemic PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> hearts. Moreover, as compared to wild type control mice, in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice phosphorylation of PLB was restored to basal levels during the vulnerable early stage (40 minutes) of reperfusion. Thus, loss of PI3K&#x003b3; results in marked dysregulation of the RISK pathway and phospholamban.</p></sec><sec id="s2d"><title>Kinase Dependency of PI3K&#x003b3; during M I/R</title><p>PI3K&#x003b3; exerts kinase-dependent and kinase-independent functions <xref ref-type="bibr" rid="pone.0009350-Patrucco1">&#x0005b;12&#x0005d;</xref>. To address the issue of kinase dependency we subjected wild type, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice, and PI3K&#x003b3; kinase-dead knock-in mice (PI3K&#x003b3;<sup>KD/KD</sup>) to M I/R injury. Whereas PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice again exhibited severe infarction following M I/R injury, PI3K&#x003b3;<sup>KD/KD</sup> mice displayed cardiac damage that was comparable to wild type control mice (<xref ref-type="fig" rid="pone-0009350-g005">Figure 5A&#x02013;E</xref>). These differences between PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice and PI3K&#x003b3;<sup>KD/KD</sup> as well as control mice were already evident at 3 and 24 hours of reperfusion (<xref ref-type="fig" rid="pone-0009350-g005">Fig. 5A&#x02013;C</xref>). PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice again showed severely compromised cardiac contractility and fractional shorting following M I/R injury. By contrast, the observed reduction in M I/R-induced infarction size in PI3K&#x003b3;<sup>KD/KD</sup> mice translated into impaired cardiac contractility that was again comparable to that of wild type mice (<xref ref-type="fig" rid="pone-0009350-g005">Figure 5F, G</xref>). Thus, the cardioprotective function of PI3K&#x003b3; during M I/R injury appears to be independent of its kinase activity. However, PI3K&#x003b3;<sup>KD/KD</sup> mice exhibited a cardiac injury similar to wild type animals.</p><fig id="pone-0009350-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009350.g005</object-id><label>Figure 5</label><caption><title>PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> lipid kinase activity is not required for cardioprotection.</title><p>(<bold>A</bold>) TroponinT levels measured after 30 minutes of ischemia and 3 hours of reperfusion are comparable between PI3K&#x003b3;<sup>KD/KD</sup> (KD) and control wild type (WT) mice. In total PI3K&#x003b3; knock-out (KO) mice TroponinT levels are significantly increased (&#x0002a;p&#x0003c;0.05). n&#x0200a;&#x0003d;&#x0200a;13 for WT and KO, n&#x0200a;&#x0003d;&#x0200a;11 for KD mice. (<bold>B</bold>) No significant difference in the area at risk (AAR)/left ventricle (LV) in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO), PI3K&#x003b3;<sup>KD/KD</sup> (KD), and control WT mice. Data are at 24 hours after M/I injury. (<bold>C</bold>) PI3K&#x003b3; KO, but not PI3K&#x003b3;<sup>KD/KD</sup> (KD) mice display a markedly increased area of infarction/area at risk (AAR) 24 hours after reperfusion evaluated by TTCstaining. n&#x0200a;&#x0003d;&#x0200a;6 per group. &#x0002a;p&#x0003c;0.05. NS&#x0200a;&#x0003d;&#x0200a;not significant. (<bold>D</bold>) Representative left ventricular Trichrome-stained sections from the basis (left) to the apex (right) of hearts from wild type (WT), PI3K&#x003b3;<sup>KD/KD</sup> knock-in (KD), and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) mice challenged with 30 minutes of ischemia plus 1 week of reperfusion. Arrows represent infarcted regions. Bars indicate 1 mm. (<bold>E</bold>) PI3K&#x003b3;<sup>KD/KD</sup> (KD) mice display similar infarctions/left ventricle (LV) compared to wild type controls after 30 minutes of ischemia and 1 week of reperfusion. Data from PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) are also shown. n&#x0200a;&#x0003d;&#x0200a;6 per group. (<bold>F</bold>) PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO), but not PI3K&#x003b3;<sup>KD/KD</sup> knock-in (KD) mice exhibit a significant greater impairment in percentage fractional shortening (FS) relative to WT controls after 30 minutes of ischemia and 1 week of reperfusion. n&#x0200a;&#x0003d;&#x0200a;6 per group. Note that the data are calculated to baseline FS of the respective genotype. All bar graphs show mean values &#x0002b;/&#x02212; SEM. &#x0002a;p&#x0003c;0.05. (<bold>G</bold>) Representative M-mode echocardiography of wild type (WT), PI3K&#x003b3;<sup>KD/KD</sup> knock-in (KD), and PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO) mice one week after M I/R injury. Note, that baseline contractility is enhanced in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (KO), but not PI3K&#x003b3;<sup>KD/KD</sup> knock-in (KD) mice as reported previously <xref ref-type="bibr" rid="pone.0009350-Crackower1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Patrucco1">&#x0005b;12&#x0005d;</xref>. Bars indicate 50 ms (horizontal) and 1 mm (vertical).</p></caption><graphic xlink:href="pone.0009350.g005"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>In the current study we surprisingly observed little requirement for PI3K&#x003b3; during inflammation associated with M I/R injury. Genetic evidence has implicated PI3K&#x003b3; as a pro-inflammatory intracellular signaling component important for neutrophil chemotaxis <xref ref-type="bibr" rid="pone.0009350-Hirsch1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Sasaki1">&#x0005b;9&#x0005d;</xref>. <italic>In vivo</italic>, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice have been shown defective in diverse models of inflammation, including acute peritonitis <xref ref-type="bibr" rid="pone.0009350-Hirsch1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Sasaki1">&#x0005b;9&#x0005d;</xref> and delayed type hypersensitivity <xref ref-type="bibr" rid="pone.0009350-DelPrete1">&#x0005b;19&#x0005d;</xref>. In addition, PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice develop attenuated atherosclerosis <xref ref-type="bibr" rid="pone.0009350-Chang1">&#x0005b;20&#x0005d;</xref>. While loss of PI3K&#x003b3; alone may slow neutrophil migration <xref ref-type="bibr" rid="pone.0009350-Heit1">&#x0005b;21&#x0005d;</xref>, this loss does not appear to affect inflammation even in the early stages of our M I/R injury model. It has been shown that <italic>in vivo</italic> PI3K&#x003b3; cooperates with PI3K&#x003b4; to promote efficient neutrophil migration in response to chemokines and pro-inflammatory cytokines such as TNF-&#x003b1; <xref ref-type="bibr" rid="pone.0009350-Liu1">&#x0005b;22&#x0005d;</xref>. Most importantly, our bone marrow transplantation experiments exclude a requirement for PI3K&#x003b3; in cardiac inflammation following M I/R injury.</p><p>Enhanced contractility by increased PLB phosphorylation <xref ref-type="bibr" rid="pone.0009350-Maroko1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Cross1">&#x0005b;24&#x0005d;</xref> and/or reduced RISK signaling via AKT and ERK1/2 <xref ref-type="bibr" rid="pone.0009350-Hausenloy1">&#x0005b;2&#x0005d;</xref> could contribute to the severe injury phenotype we observed in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice. We found that knock-in mice lacking the PI3K&#x003b3; kinase activity (PI3K&#x003b3;<sup>KD/KD</sup>) display an M I/R injury phenotype that is similar to wild type animals. Therefore, the detrimental outcome observed in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> animals appears to be due to kinase-independent events, possibly via phospholamban hyperphospholryation and hypercontractility. PI3K&#x003b3; blockers have entered clinical development for chronic inflammation and heart attacks in humans <xref ref-type="bibr" rid="pone.0009350-Doukas1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Rommel1">&#x0005b;25&#x0005d;</xref>. Our data on PI3K&#x003b3; in M I/R injury suggest that specific inhibition of PI3K&#x003b3; will not result in any overall improvement concerning cardiac function and the extent of injury. Moreover, we observed a loss of RISK activation in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice, suggesting that treatment with PI3K&#x003b3; blockers may interfere with these early pro-survival signals in some contexts. Of note, the observed loss of immediate RISK activation itself does not appear to compromise M I/R outcome in our model. These data are consistent with other recent studies questioning the cardioprotective role of RISK <xref ref-type="bibr" rid="pone.0009350-Musiolik1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Skyschally1">&#x0005b;27&#x0005d;</xref>. Similar to our first in vivo evidence on M I/R injury using mutant mice and kinase-dead knock-in mice, previous work has shown that PI3K&#x003b3; is an important signaling pathway that controls ischemic preconditioning <italic>in vitro</italic><xref ref-type="bibr" rid="pone.0009350-Ban1">&#x0005b;28&#x0005d;</xref>, arguing that if anything, strategies to activate, not inhibit, PI3K&#x003b3; may improve outcome for patients with ischemic heart disease.</p><p>The present study provides evidence that PI3K&#x003b3; is cardioprotective <italic>in vivo</italic> in a mouse model of myocardial ischemia/reperfusion. Surprisingly, the severe cardiac damage observed in PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> mice occurs very rapidly and is not influenced by PI3K&#x003b3; expression within the hematopoietic compartment, suggesting that PI3K&#x003b3; exerts a cell autonomous protective function in cardiomyocytes. Using kinase dead knock-in mice, these detrimental effects were mapped to be independent of PI3K&#x003b3; lipid kinase activity. However, loss of PI3K&#x003b3; catalytic activity does not translate into a beneficial outcome but could negatively influence RISK signaling during the acute phase of reperfusion. In conclusion, our genetic data indicate that specific inhibition of PI3K&#x003b3; is not cardioprotective. Therefore, treatment of acute infarctions with PI3K&#x003b3; inhibitors should proceed with caution.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4a"><title>Mice/Ethics Statement</title><p>PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup> (p110&#x003b3;<sup>&#x02212;/&#x02212;</sup>) and kinase-dead knock-in PI3K&#x003b3;<sup>KD/KD</sup> mice have been previously described <xref ref-type="bibr" rid="pone.0009350-Sasaki1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Patrucco1">&#x0005b;12&#x0005d;</xref> and were backcrossed onto a C57BL/6 background for at least 8 generations. Only male animals were used for the experiments. Animals were handled in accordance with institutional guidelines all experiments were approved by the Austrian Federal Ministry of Science and Research (GZ: BMBWK 66.011/0061BrGT/2006), and in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85&#x02013;23, revised 1996).</p></sec><sec id="s4b"><title>Surgical Procedure and Experimental Protocol</title><p>PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup>, PI3K&#x003b3;<sup>KD/KD</sup>, and control mice were randomised into a three-hour, 24-hour, one-week, and three-week reperfusion groups and underwent <italic>in vivo</italic> reversible LAD ligation as described <xref ref-type="bibr" rid="pone.0009350-Metzler1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009350-Stuhlinger1">&#x0005b;30&#x0005d;</xref>. Briefly, following sedation, tracheotomy, ventilation, and thoracotomy, the LAD was reversibly ligated aided by a PE tube. After 30 minutes of ischemia, the PE tube was removed and reperfusion was visually confirmed. The overall peri- and post-procedural mortality was below 10&#x00025; (control mice: 5,7&#x00025;; PI3K&#x003b3;<sup>&#x02212;/&#x02212;</sup>: 6,1&#x00025;; PI3K&#x003b3;<sup>KD/KD</sup>: 9,7&#x00025;).</p></sec><sec id="s4c"><title>Infarct Evaluation</title><p>Heparinized blood was collected from the retrobulbar vein plexus. Plasma levels of troponinT were evaluated as a biomarker for cardiac damage using a quantitative assay (Roche Diagnostics, Austria). Moreover, hearts were fixed in 4&#x00025; formaldehyde overnight and embedded in paraffin. Three 5-&#x000b5;m sections were cut from defined levels of the left ventricle, stained with hematoxylin and eosin (H&#x00026;E). Infarct sizes were analyzed using Axio Imager M1 (Zeiss, Axiovert, Jena, Germany) and TissueFAXS software package (TissueGnostics, Vienna, Austria). In addition, formalin-fixed heart sections were stained with Trichrome and Aniline Blue to detect differences in collagen deposition and scar size. Using a light microscope (Axioskop2 equipped with AxioCam MRc5, Zeiss), Axio Vision 4.0 (Zeiss), and Adobe Photoshop CS3, the mean values of inflammatory infiltrate were determined within 3&#x000d7;40 visual fields of each area of infarction. To evaluate the size of the infarction in relation to the area at risk (AAR) and left ventricle size, we performed 2,3,5-triphenyltetrazolium chloride (TTC) staining: The LAD was firmly re-occluded after 3 hours of reperfusion and 0.5 ml of Evan's blue was injected into the left ventricle. The presence of Evan's blue indicates perfusion, whereas its absence indicates lack of perfusion <xref ref-type="bibr" rid="pone.0009350-Griswold1">&#x0005b;31&#x0005d;</xref>. Sections from the left ventricles were put into a 2&#x00025; TTC solution (Sigma) and stained for 15 minutes under constant shaking. Whereas brick red areas indicate viable myocardium, white regions demarcate tissue injury. Left ventricle size (LV), area at risk (AAR) and infarct area (Inf) were assessed by a blinded investigator. Measurements from multiple heart slices were averaged and Inf/AAR and AAR/LV calculated.</p></sec><sec id="s4d"><title>Echocardiography</title><p>Myocardial contractility was determined by transthoracic echocardiography using a sector scanner (AcuNav 10MHz, Acuson Sequoia C256, Acuson Corporation Mountain View, CA) and Visualsonics Vevo 770. Short-axis 2D-targeted M-mode images of the left ventricle were obtained. Fractional shortening (FS) was calculated from digital images by using a standard formula.</p></sec><sec id="s4e"><title>Bone Marrow Transplantation</title><p>Six to eight week-old recipient mice underwent a lethal total-body irradiation (1000 Rad). Freshly isolated total host bone marrow cells were then injected into the lateral tail vein of syngenic recipient mice (5&#x000d7;10<sup>6</sup> cells per mouse) 24 hours after irradiation. PCR analyses of blood cells and tail DNA indicated that &#x0223c;95&#x00025; of circulating leukocytes were of donor origin.</p></sec><sec id="s4f"><title>Preparation of Cardiac Samples and Immunoblot Analysis</title><p>Hearts were quickly removed and the area at risk from the left ventricle was immediately snap-frozen in liquid nitrogen. Proteins were extracted using T-PER Tissue Protein Extraction Reagent containing a Halt Protease and Phosphatase Inhibitor Cocktail (PIERCE, Rockford, USA). Protein extracts (20&#x000b5;g) were subjected to Western blot analysis with antibodies against phospho-ERK (T202/Y204, Cell Signaling), ERK (Cell Signaling), phospho-PLB (S16, Upstate), PLB (clone A1; Upstate), phospho-AKT (S473, R&#x00026;D Systems), phospho-AKT (T308, Cell Signaling), and AKT (Cell Signaling). For Western blot analysis of PI3K&#x003b3;, 40&#x000b5;g of protein was used.</p></sec><sec id="s4g"><title>Immunohistochemistry</title><p>Serial 5&#x000b5;m sections were cut from cryo-preserved tissue blocks, fixed in ice-cold acetone for 10 minutes and washed with TRIS buffer for 3&#x000d7;3 minutes. Sections were then blocked with MeOH and H<sub>2</sub>O<sub>2</sub>, washed with TRIS buffer, stained with a rabbit antibody against phospho-Akt (Ser473; R&#x00026;D Systems) and subsequently counterstained with hematoxylin.</p></sec><sec id="s4h"><title>Statistical Analysis</title><p>All data are expressed as mean values &#x000b1;SEM. Statistical analyses were performed using the Student's <italic>t</italic> test or one-way ANOVA followed by a post hoc multiple comparison test where appropriate (SPSS software). Probability values &#x0003e;0.05 were considered significant.</p></sec></sec></body><back><ack><p>This work is dedicated to Professor Otmar Pachinger on the occasion of his 65<sup>th</sup> birthday.</p></ack><ref-list><title>References</title><ref id="pone.0009350-Baines1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baines</surname><given-names>CP</given-names></name></person-group><year>2009</year><article-title>The mitochondrial permeability transition pore and ischemia-reperfusion injury.</article-title><source>Basic Res Cardiol</source><volume>104</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">19242640</pub-id></mixed-citation></ref><ref id="pone.0009350-Hausenloy1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><year>2007</year><article-title>Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection.</article-title><source>Heart Fail Rev</source><volume>12</volume><fpage>217</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">17541822</pub-id></mixed-citation></ref><ref id="pone.0009350-Nian1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nian</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Khaper</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name></person-group><year>2004</year><article-title>Inflammatory cytokines and postmyocardial infarction remodeling.</article-title><source>Circ Res</source><volume>94</volume><fpage>1543</fpage><lpage>1553</lpage><pub-id pub-id-type="pmid">15217919</pub-id></mixed-citation></ref><ref id="pone.0009350-Yaoita1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaoita</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Maehara</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>Y</given-names></name></person-group><year>2000</year><article-title>Apoptosis in relevant clinical situations: contribution of apoptosis in myocardial infarction.</article-title><source>Cardiovasc Res</source><volume>45</volume><fpage>630</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">10728384</pub-id></mixed-citation></ref><ref id="pone.0009350-Fisher1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>TC</given-names></name><name><surname>Meiselmann</surname><given-names>HJ</given-names></name></person-group><year>1994</year><article-title>Polymorphonuclear leukocytes in ischemic vascular disease.</article-title><source>Thromb Res</source><volume>74</volume><issue>Suppl 1</issue><fpage>S21</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">8073399</pub-id></mixed-citation></ref><ref id="pone.0009350-Brodde1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodde</surname><given-names>OE</given-names></name><name><surname>Hillemann</surname><given-names>S</given-names></name><name><surname>Kunde</surname><given-names>K</given-names></name><name><surname>Vogelsang</surname><given-names>M</given-names></name><name><surname>Zerkowski</surname><given-names>HR</given-names></name></person-group><year>1992</year><article-title>Receptor systems affecting force of contraction in the human heart and their alterations in chronic heart failure.</article-title><source>J Heart Lung Transplant</source><volume>11</volume><fpage>S164</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">1355362</pub-id></mixed-citation></ref><ref id="pone.0009350-Hawkins1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>PT</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name></person-group><year>2007</year><article-title>PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis.</article-title><source>Science</source><volume>318</volume><fpage>64</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">17916723</pub-id></mixed-citation></ref><ref id="pone.0009350-Hirsch1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Katanaev</surname><given-names>VL</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Azzolino</surname><given-names>O</given-names></name><name><surname>Pirola</surname><given-names>L</given-names></name><etal/></person-group><year>2000</year><article-title>Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation.</article-title><source>Science</source><volume>287</volume><fpage>1049</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">10669418</pub-id></mixed-citation></ref><ref id="pone.0009350-Sasaki1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Irie-Sasaki</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>Oliveira-dos-Santos</surname><given-names>AJ</given-names></name><name><surname>Stanford</surname><given-names>WL</given-names></name><etal/></person-group><year>2000</year><article-title>Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration.</article-title><source>Science</source><volume>287</volume><fpage>1040</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">10669416</pub-id></mixed-citation></ref><ref id="pone.0009350-Hawkins2"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>PT</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><name><surname>Davidson</surname><given-names>K</given-names></name><name><surname>Stephens</surname><given-names>LR</given-names></name></person-group><year>2006</year><article-title>Signalling through Class I PI3Ks in mammalian cells.</article-title><source>Biochem Soc Trans</source><volume>34</volume><fpage>647</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">17052169</pub-id></mixed-citation></ref><ref id="pone.0009350-Crackower1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crackower</surname><given-names>MA</given-names></name><name><surname>Oudit</surname><given-names>GY</given-names></name><name><surname>Kozieradzki</surname><given-names>I</given-names></name><name><surname>Sarao</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><etal/></person-group><year>2002</year><article-title>Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways.</article-title><source>Cell</source><volume>110</volume><fpage>737</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">12297047</pub-id></mixed-citation></ref><ref id="pone.0009350-Patrucco1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrucco</surname><given-names>E</given-names></name><name><surname>Notte</surname><given-names>A</given-names></name><name><surname>Barberis</surname><given-names>L</given-names></name><name><surname>Selvetella</surname><given-names>G</given-names></name><name><surname>Maffei</surname><given-names>A</given-names></name><etal/></person-group><year>2004</year><article-title>PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects.</article-title><source>Cell</source><volume>118</volume><fpage>375</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">15294162</pub-id></mixed-citation></ref><ref id="pone.0009350-Oudit1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudit</surname><given-names>GY</given-names></name><name><surname>Crackower</surname><given-names>MA</given-names></name><name><surname>Eriksson</surname><given-names>U</given-names></name><name><surname>Sarao</surname><given-names>R</given-names></name><name><surname>Kozieradzki</surname><given-names>I</given-names></name><etal/></person-group><year>2003</year><article-title>Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.</article-title><source>Circulation</source><volume>108</volume><fpage>2147</fpage><lpage>2152</lpage><pub-id pub-id-type="pmid">12963636</pub-id></mixed-citation></ref><ref id="pone.0009350-Curcio1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curcio</surname><given-names>A</given-names></name><name><surname>Noma</surname><given-names>T</given-names></name><name><surname>Naga Prasad</surname><given-names>SV</given-names></name><name><surname>Wolf</surname><given-names>MJ</given-names></name><name><surname>Lemaire</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling.</article-title><source>Am J Physiol Heart Circ Physiol</source><volume>291</volume><fpage>H1754</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">16699071</pub-id></mixed-citation></ref><ref id="pone.0009350-Nienaber1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nienaber</surname><given-names>JJ</given-names></name><name><surname>Tachibana</surname><given-names>H</given-names></name><name><surname>Naga Prasad</surname><given-names>SV</given-names></name><name><surname>Esposito</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><etal/></person-group><year>2003</year><article-title>Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure.</article-title><source>J Clin Invest</source><volume>112</volume><fpage>1067</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">14523044</pub-id></mixed-citation></ref><ref id="pone.0009350-Doukas1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doukas</surname><given-names>J</given-names></name><name><surname>Wrasidlo</surname><given-names>W</given-names></name><name><surname>Noronha</surname><given-names>G</given-names></name><name><surname>Dneprovskaia</surname><given-names>E</given-names></name><name><surname>Hood</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.</article-title><source>Biochem Soc Trans</source><volume>35</volume><fpage>204</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">17371238</pub-id></mixed-citation></ref><ref id="pone.0009350-Ruckle1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruckle</surname><given-names>T</given-names></name><name><surname>Schwarz</surname><given-names>MK</given-names></name><name><surname>Rommel</surname><given-names>C</given-names></name></person-group><year>2006</year><article-title>PI3Kgamma inhibition: towards an &#x02018;aspirin of the 21st century&#x02019;?</article-title><source>Nat Rev Drug Discov</source><volume>5</volume><fpage>903</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">17080027</pub-id></mixed-citation></ref><ref id="pone.0009350-Kerfant1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerfant</surname><given-names>BG</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Lorenzen-Schmidt</surname><given-names>I</given-names></name><name><surname>Wilson</surname><given-names>LS</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes.</article-title><source>Circ Res</source><volume>101</volume><fpage>400</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">17615371</pub-id></mixed-citation></ref><ref id="pone.0009350-DelPrete1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Prete</surname><given-names>A</given-names></name><name><surname>Vermi</surname><given-names>W</given-names></name><name><surname>Dander</surname><given-names>E</given-names></name><name><surname>Otero</surname><given-names>K</given-names></name><name><surname>Barberis</surname><given-names>L</given-names></name><etal/></person-group><year>2004</year><article-title>Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice.</article-title><source>Embo J</source><volume>23</volume><fpage>3505</fpage><lpage>3515</lpage><pub-id pub-id-type="pmid">15318168</pub-id></mixed-citation></ref><ref id="pone.0009350-Chang1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JD</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Schvartz</surname><given-names>E</given-names></name><name><surname>Lichtenstein</surname><given-names>AH</given-names></name><etal/></person-group><year>2007</year><article-title>Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis.</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><fpage>8077</fpage><lpage>8082</lpage><pub-id pub-id-type="pmid">17483449</pub-id></mixed-citation></ref><ref id="pone.0009350-Heit1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heit</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Colarusso</surname><given-names>P</given-names></name><name><surname>Puri</surname><given-names>KD</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group><year>2008</year><article-title>PI3K accelerates, but is not required for, neutrophil chemotaxis to fMLP.</article-title><source>J Cell Sci</source><volume>121</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">18187452</pub-id></mixed-citation></ref><ref id="pone.0009350-Liu1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Puri</surname><given-names>KD</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group><year>2007</year><article-title>Leukocyte PI3Kgamma and PI3Kdelta have temporally distinct roles for leukocyte recruitment in vivo.</article-title><source>Blood</source><volume>110</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">17488877</pub-id></mixed-citation></ref><ref id="pone.0009350-Maroko1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maroko</surname><given-names>PR</given-names></name><name><surname>Kjekshus</surname><given-names>JK</given-names></name><name><surname>Sobel</surname><given-names>BE</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Covell</surname><given-names>JW</given-names></name><etal/></person-group><year>1971</year><article-title>Factors influencing infarct size following experimental coronary artery occlusions.</article-title><source>Circulation</source><volume>43</volume><fpage>67</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">5540853</pub-id></mixed-citation></ref><ref id="pone.0009350-Cross1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>HR</given-names></name><name><surname>Kranias</surname><given-names>EG</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name><name><surname>Steenbergen</surname><given-names>C</given-names></name></person-group><year>2003</year><article-title>Ablation of PLB exacerbates ischemic injury to a lesser extent in female than male mice: protective role of NO.</article-title><source>Am J Physiol Heart Circ Physiol</source><volume>284</volume><fpage>H683</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">12388218</pub-id></mixed-citation></ref><ref id="pone.0009350-Rommel1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rommel</surname><given-names>C</given-names></name><name><surname>Camps</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name></person-group><year>2007</year><article-title>PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?</article-title><source>Nat Rev Immunol</source><volume>7</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">17290298</pub-id></mixed-citation></ref><ref id="pone.0009350-Musiolik1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musiolik</surname><given-names>J</given-names></name><name><surname>van Caster</surname><given-names>P</given-names></name><name><surname>Skyschally</surname><given-names>A</given-names></name><name><surname>Boengler</surname><given-names>K</given-names></name><name><surname>Gres</surname><given-names>P</given-names></name><etal/></person-group><year>2009</year><article-title>Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs.</article-title><source>Cardiovasc Res</source></mixed-citation></ref><ref id="pone.0009350-Skyschally1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skyschally</surname><given-names>A</given-names></name><name><surname>van Caster</surname><given-names>P</given-names></name><name><surname>Boengler</surname><given-names>K</given-names></name><name><surname>Gres</surname><given-names>P</given-names></name><name><surname>Musiolik</surname><given-names>J</given-names></name><etal/></person-group><year>2009</year><article-title>Ischemic postconditioning in pigs: no causal role for RISK activation.</article-title><source>Circ Res</source><volume>104</volume><fpage>15</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">19038864</pub-id></mixed-citation></ref><ref id="pone.0009350-Ban1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>K</given-names></name><name><surname>Cooper</surname><given-names>AJ</given-names></name><name><surname>Samuel</surname><given-names>S</given-names></name><name><surname>Bhatti</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning.</article-title><source>Circ Res</source><volume>103</volume><fpage>643</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">18688045</pub-id></mixed-citation></ref><ref id="pone.0009350-Metzler1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzler</surname><given-names>B</given-names></name><name><surname>Mair</surname><given-names>J</given-names></name><name><surname>Lercher</surname><given-names>A</given-names></name><name><surname>Schaber</surname><given-names>C</given-names></name><name><surname>Hintringer</surname><given-names>F</given-names></name><etal/></person-group><year>2001</year><article-title>Mouse model of myocardial remodelling after ischemia: role of intercellular adhesion molecule-1.</article-title><source>Cardiovasc Res</source><volume>49</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">11164850</pub-id></mixed-citation></ref><ref id="pone.0009350-Stuhlinger1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuhlinger</surname><given-names>MC</given-names></name><name><surname>Conci</surname><given-names>E</given-names></name><name><surname>Haubner</surname><given-names>BJ</given-names></name><name><surname>Stocker</surname><given-names>EM</given-names></name><name><surname>Schwaighofer</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury.</article-title><source>Cardiovasc Res</source><volume>75</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">17559823</pub-id></mixed-citation></ref><ref id="pone.0009350-Griswold1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griswold</surname><given-names>DE</given-names></name><name><surname>Hillegass</surname><given-names>LM</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Egan</surname><given-names>JW</given-names></name><name><surname>Smith</surname><given-names>EF</given-names><suffix>3rd</suffix></name></person-group><year>1988</year><article-title>Method for quantification of myocardial infarction and inflammatory cell infiltration in rat cardiac tissue.</article-title><source>J Pharmacol Methods</source><volume>20</volume><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">2853255</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Supported by grants from IMBA and EuGeneHeart (EU grant) to J.M.P. and from the &#x000d6;sterreichische Kardiologische Gesellschaft and Medizinischer Forschungsfond Tirol to B.M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>